The following is a summary of “Mendelian randomization of plasma proteomics identifies novel ALS-associated proteins and their GO enrichment and KEGG pathway analyses,” published in the March 2025 ...

Dr. Guy A. Rouleau discusses his vision for revolutionizing neurological disease research through open science, emphasizing ...

A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in Canada for adults with an ultra-rare form of the disease.

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

As global populations age, neurological disorders such as Alzheimer's, Parkinson's, and epilepsy become more prevalent.

Northwestern Medicine scientists have uncovered new insights into how neurofilaments act like Velcro in neurodegenerative ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Texas Medical Center protest was part of a nationwide "Stand Up for Science" day of protest following the National Institutes ...